Publications
5674 Results
- Journal / Conference
- Cancer Epidemiology, Biomarkers and Prevention 23(12):2895-2905;
- Year
- 2014
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID25242051
- PMC
- PMC4257858
- Study Number(s)
- S0000
Retention of black and white participants in the Selenium and Vitamin E Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S0000)
- Journal / Conference
- Journal of Urology Vol. 191, No. 4S, Suppl., p. e283 (PD10-04); poster; American Urological Assn Annual Meeting (May 16 -21, 2014, Orlando, FL);
- Year
- 2014
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/E2805
Lymphadenectomy at the time of surgery for high risk localized RCC: results from the ASSURE adjuvant trial (ECOG 2805)
- Journal / Conference
- Journal of Clinical Oncology 32(suppl 4; abstr LBA287), oral; ASCO GU Cancers Symposium
- Year
- 2014
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/R0524
The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer
- Journal / Conference
- Radiotherapy and Oncology 112(3):418-424;
- Year
- 2014
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID24996454
- PMC
- PMC4258107
- Study Number(s)
- S0713
Consequences of anorectal cancer atlas implementation in the cooperative group setting: radiobiologic analysis of a prospective randomized in silico target delineation study
- Journal / Conference
- Annals of Oncology 25 (Suppl 4): iv1 - mdu438.66; ESMO 2014 Congress (Sept 26-30, 2014, Madrid, Spain), oral presentation;
- Year
- 2014
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
CALGB/SWOG C80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
- Journal / Conference
- Annals of Oncology 25 (Suppl 4): iv1 - mdu438.66; ESMO 2014 Congress (September 26-30, 2014, Madrid, Spain), poster presentation;
- Year
- 2014
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80702
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: a prospective pooled analysis of > 11,500 patients from 6 Phase III trials of adjuvant therapy duration with FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) for stage III colon cancer
- Journal / Conference
- Lancet Oncology 15(9):986-996
- Year
- 2014
- Research Committee(s)
- Leukemia
- PMID
- PMID25008258
- PMC
- PMC4137593
- Study Number(s)
- S0106
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in acute myeloid leukaemia by reducing relapse risk: A source data meta-analysis of randomised trials in adults
- Journal / Conference
- Blood 124(15):2400-2407;
- Year
- 2014
- Research Committee(s)
- Leukemia
- PMID
- PMID25145343
- PMC
- PMC4192751
- Study Number(s)
- S0106
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report
- Journal / Conference
- British Journal of Cancer 111(6):1065-1071;
- Year
- 2014
- Research Committee(s)
- Breast
- PMID
- PMID25117817
- PMC
- PMC4453859
- Study Number(s)
- N9831
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
- Journal / Conference
- Blood 124(21):3676; American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster;
- Year
- 2014
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106